Dec 16,2021

Study: 83% of Oncologists Believe Real-World Data Is Critical to Accelerating Cancer Research and Treatment

COTA announced insights from a study of practicing oncologists that found 83 percent of oncologists surveyed believe real-world data is critical to accelerating the development of potentially life-saving cancer drugs and treatments.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 17,2021

Israeli research institute makes great contributions to cancer research

Graduates and professors of Israeli institute the Technion have made large contributions in the field of cancer research and treatment. Technion professor Yuval Shaked, together with startup OncoHost, is responsible for the creation of a blood test that will help doctors to provide personalized treatment plans to cancer patients, and plans for clinical trials in the UK in collaboration with the country’s National Healthcare System are in the works.

CLINICAL STUDY

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 20,2021

OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, recently announced a research collaboration with Lung Biobank Heidelberg, a member of BioMaterialBank Heidelberg (BMBH) and the German Center for Lung Research (DZL).

COLLABORATION PARTNERSHIP

#r&d

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 09,2020

Two leading university hospitals implement Kaiku Health in Central Europe

Kaiku Health is strengthening its foothold in Central Europe as the Geneva University Hospitals (HUG) in Switzerland and University Hospital Schleswig-Holstein Lübeck in Germany will implement Kaiku Health in the symptom management and patient-reported outcome monitoring of their cancer patients. Kaiku Health was piloted at the Geneva University Hospitals (HUG) in 2019. The platform will be gradually provided for all patients who receive chemotherapy for local or metastatic breast, colorectal or lung cancer. University Hospital Schleswig-Holstein Lübeck will implement Kaiku Health into the monitoring and management of toxicities of lung cancer patients treated with immunotherapies and receiving either mono- or combination therapies.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 09,2020

Bayer and Exscientia Collaborate to Leverage the Potential of Artificial Intelligence in Cardiovascular and Oncology Drug Discovery

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities. They aim to identify and optimize novel lead structures for potential drug candidates to treat cardiovascular and oncological diseases. Exscientia may be eligible to receive up to EUR 240 million, including upfront and research payments, near term and clinical milestones. As part of the agreement, Exscientia may also receive sales royalties. Bayer owns the rights to novel lead structures generated as part of the collaboration.

COLLABORATION PARTNERSHIP

#data & technology

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 28,2020

Siemens Healthineers Presents Solutions Supporting Digital Transformation of Healthcare at Arab Health 2020

CT scanners with intelligent user guidance, AI-based software assistants for MRI and a lab system that revolutionizes workflows: Siemens Healthineers is showcasing its products and solutions according to the motto "Shaping the Future of Healthcare" at this year's Arab Health in Dubai, UAE, focusing on digital transformation of imaging and laboratory testing while improving patient experience.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jan 21,2020

OncoHost, RayBiotech Win $1M From BIRD Foundation

OncoHost, global leader in host response profiling for improved personalized cancer therapy, together with its partner RayBiotech, a leading life sciences company developing high-throughput protein detection technologies for biomarker discovery initiatives, announced today the companies have been awarded a $1 million grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

FUNDING GRANT

#platform

View Analyst & Ambassador Comments
Go to original news
Feb 10,2020

Startup develops blood test that aims to undermine tumors’ resilience

Israeli startup ONCOHOST is working on a blood test that can predict which cancer patients will respond to which treatment, and thereby figure out how to adjust prescribed therapies to prevent the recurrence of tumors.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 22,2020

Harnessing technology to fight toxicities in cancer immunotherapies

In recent years, there has been a drastic change in the treatment landscape of several advanced cancers. Cancer immunotherapies have shown to be a viable treatment option for many patients who would have otherwise had a poor prognosis with traditional treatments, such as chemotherapy. Based on the patient’s therapy and the historical trend of symptoms, Kaiku Health algorithms are capable of predicting the occurrence of up to 15 symptoms that may indicate the development of immune-related adverse events, such as skin and pulmonary toxicities.

PRODUCT

#ml

View Analyst & Ambassador Comments
Go to original news
Mar 30,2020

Top Apps for Fighting and Beating Cancer

In today’s digital age, there are apps for everything, and the same is true for cancer patients and their families. The apps we found for you are designed to help you get all the information you might need about the disease you or your loved one is facing. Belong.life is an excellent app for both cancer patients and their family members. It’s designed to mimic a social media platform – but one for cancer patients.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY